Single User License
INR 100335
Site License
INR 200670
Corporate User License
INR 301005

Service Tax Additional

select a format

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"

Alnylam Pharmaceuticals, Inc.-Product Pipeline Review-2015

Alnylam Pharmaceuticals, Inc.-Product Pipeline Review-2015

  Request for Sample Report

Executive Summary

Alnylam Pharmaceuticals, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'Alnylam Pharmaceuticals, Inc.-Product Pipeline Review-2015', provides an overview of the Alnylam Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Alnylam Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Alnylam Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Alnylam Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Alnylam Pharmaceuticals, Inc.'s pipeline products

Reasons To Buy

Evaluate Alnylam Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Alnylam Pharmaceuticals, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Alnylam Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Alnylam Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Alnylam Pharmaceuticals, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Alnylam Pharmaceuticals, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Alnylam Pharmaceuticals, Inc. Snapshot 7

Alnylam Pharmaceuticals, Inc. Overview 7

Key Information 7

Key Facts 7

Alnylam Pharmaceuticals, Inc.-Research and Development Overview 8

Key Therapeutic Areas 8

Alnylam Pharmaceuticals, Inc.-Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products-Monotherapy 12

Pipeline Products-Out-Licensed Products 13

Out-Licensed Products/Combination Treatment Modalities 14

Alnylam Pharmaceuticals, Inc.-Pipeline Products Glance 15

Alnylam Pharmaceuticals, Inc.-Late Stage Pipeline Products 15

Phase III Products/Combination Treatment Modalities 15

Alnylam Pharmaceuticals, Inc.-Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Alnylam Pharmaceuticals, Inc.-Early Stage Pipeline Products 18

IND/CTA Filed Products/Combination Treatment Modalities 18

Preclinical Products/Combination Treatment Modalities 19

Discovery Products/Combination Treatment Modalities 20

Alnylam Pharmaceuticals, Inc.-Drug Profiles 21

patisiran 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

revusiran 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

asvasiran sodium 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

ALN-CC5 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

ALN-AT3 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

ALN-PCSsc 28

Product Description 28

Mechanism of Action 28

R&D Progress 28


Product Description 29

Mechanism of Action 29

R&D Progress 29

ALNPCS-02 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

ALN-AS1 31

Product Description 31

Mechanism of Action 31

R&D Progress 31


Product Description 32

Mechanism of Action 32

R&D Progress 32


Product Description 33

Mechanism of Action 33

R&D Progress 33


Product Description 34

Mechanism of Action 34

R&D Progress 34


Product Description 35

Mechanism of Action 35

R&D Progress 35


Product Description 36

Mechanism of Action 36

R&D Progress 36


Product Description 38

Mechanism of Action 38

R&D Progress 38


Product Description 39

Mechanism of Action 39

R&D Progress 39


Product Description 40

Mechanism of Action 40

R&D Progress 40


Product Description 41

Mechanism of Action 41

R&D Progress 41

ALNAC-3 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

ALNGO-1 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Cell Therapy for Cancer and Viral Infections 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

dsP21-322-2'F 45

Product Description 45

Mechanism of Action 45

R&D Progress 45


Product Description 46

Mechanism of Action 46

R&D Progress 46

RNAi Oligonucleotide for Undisclosed Indication 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

RNAi Oligonucleotides for Cardiovascular and Metabolic Disorders 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

RNAi Oligonucleotides for Genetic Diseases 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

RNAi Oligonucleotides for Hepatic Infections 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Alnylam Pharmaceuticals, Inc.-Pipeline Analysis 51

Alnylam Pharmaceuticals, Inc.-Pipeline Products by Target 51

Alnylam Pharmaceuticals, Inc.-Pipeline Products by Route of Administration 53

Alnylam Pharmaceuticals, Inc.-Pipeline Products by Molecule Type 54

Alnylam Pharmaceuticals, Inc.-Pipeline Products by Mechanism of Action 55

Alnylam Pharmaceuticals, Inc.-Recent Pipeline Updates 57

Alnylam Pharmaceuticals, Inc.-Dormant Projects 79

Alnylam Pharmaceuticals, Inc.-Locations And Subsidiaries 80

Head Office 80

Other Locations & Subsidiaries 80

Appendix 81

Methodology 81

Coverage 81

Secondary Research 81

Primary Research 81

Expert Panel Validation 81

Contact Us 81

Disclaimer 82

List of Tables

Alnylam Pharmaceuticals, Inc., Key Information 7

Alnylam Pharmaceuticals, Inc., Key Facts 7

Alnylam Pharmaceuticals, Inc.-Pipeline by Indication, 2015 9

Alnylam Pharmaceuticals, Inc.-Pipeline by Stage of Development, 2015 11

Alnylam Pharmaceuticals, Inc.-Monotherapy Products in Pipeline, 2015 12

Alnylam Pharmaceuticals, Inc.-Out-Licensed Products in Pipeline, 2015 13

Alnylam Pharmaceuticals, Inc.-Out-Licensed Products/ Combination Treatment Modalities, 2015 14

Alnylam Pharmaceuticals, Inc.-Phase III, 2015 15

Alnylam Pharmaceuticals, Inc.-Phase II, 2015 16

Alnylam Pharmaceuticals, Inc.-Phase I, 2015 17

Alnylam Pharmaceuticals, Inc.-IND/CTA Filed, 2015 18

Alnylam Pharmaceuticals, Inc.-Preclinical, 2015 19

Alnylam Pharmaceuticals, Inc.-Discovery, 2015 20

Alnylam Pharmaceuticals, Inc.-Pipeline by Target, 2015 52

Alnylam Pharmaceuticals, Inc.-Pipeline by Route of Administration, 2015 53

Alnylam Pharmaceuticals, Inc.-Pipeline by Molecule Type, 2015 54

Alnylam Pharmaceuticals, Inc.-Pipeline Products by Mechanism of Action, 2015 56

Alnylam Pharmaceuticals, Inc.-Recent Pipeline Updates, 2015 57

Alnylam Pharmaceuticals, Inc.-Dormant Developmental Projects,2015 79

Alnylam Pharmaceuticals, Inc., Subsidiaries 80

List of Figures

Alnylam Pharmaceuticals, Inc.-Pipeline by Top 10 Indication, 2015 9

Alnylam Pharmaceuticals, Inc.-Pipeline by Stage of Development, 2015 11

Alnylam Pharmaceuticals, Inc.-Monotherapy Products in Pipeline, 2015 12

Alnylam Pharmaceuticals, Inc.-Out-Licensed Products in Pipeline, 2015 13

Alnylam Pharmaceuticals, Inc.-Pipeline by Top 10 Target, 2015 51

Alnylam Pharmaceuticals, Inc.-Pipeline by Top 10 Route of Administration, 2015 53

Alnylam Pharmaceuticals, Inc.-Pipeline by Top 10 Molecule Type, 2015 54

Alnylam Pharmaceuticals, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 55

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Current R&D Portfolio of Alnylam Pharmaceuticals, Inc.; Alnylam Pharmaceuticals, Inc. - Key Therapeutics; Alnylam Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Alnylam Pharmaceuticals, Inc. - News; Alnylam Pharmaceuticals, Inc. - Latest Updates; Alnylam Pharmaceuticals, Inc. - Pipeline; Alnylam Pharmaceuticals, Inc. - Discontinued/Dormant Projects

Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]